Side-Effect Management

Strategies for Managing Postradiotherapy Cerebral Radiation Necrosis in Nontarget Brain Tissue

By

Bryant Furlow

This review seeks to shed light on a relatively common but poorly understood adverse effect of radiotherapy for primary and metastatic brain or head and neck tumors.

Treatment With PI3K Inhibitors Is Associated With a Number of Adverse Events and Toxicities

By

Tiffany Garbutt, PhD

Despite improved survival in patients with B cell malignancies who are treated with PI3K inhibitors, researchers found incidences of pneumonitis, infections, and sepsis are higher in these patients.

Assessing VTE Risk Based on Presence of Elevated Biomarkers Provides Better Risk Stratification Than Current Methods

By

Tiffany Garbutt, PhD

New scoring method provides a more nuanced risk stratification of VTE than the Khorana score in ambulatory patients with cancer.

Interim Phase 2 Analysis of Luspatercept in Treatment of Myelofibrosis-Associated Anemia

By

Vicki Moore, PhD

Data from an ongoing trial of luspatercept, an erythroid maturation agent, in patients with myelofibrosis and anemia shows promise of clinically significant activity with low level of grade 3/4 adverse effects.

Risk of Cardiac Heart Failure, Arrythmia Increased With Anthracycline for Lymphoma

By

Tiffany Garbutt, PhD

A prospective study followed more than 3000 patients with lymphoma to determine the potential risk for developing anthracycline-induced CVD.

Corticosteroids May Be Effective for Managing Cytokine Release Syndrome Associated With CAR-T Therapy

By

Tiffany Garbutt, PhD

Researchers sought to determine if corticosteroids can be used to effectively manage CRS in patients undergoing CAR-T therapy without negatively influencing outcomes.

Early Steroid Use May Mitigate Adverse Effects Associated With Axicabtagene Ciloleucel CAR-T Therapy

By

Tiffany Garbutt, PhD

In a safety expansion of the ZUMA-1 study, researchers found that steroids may reduce incidence of CRS and neurologic events associated with CAR-T therapy in patients with relapsed/refractory large B cell lymphoma.

Elevated Risk for CVD Mortality Observed in U.S. Cancer Patients

Risk highest in the year after diagnosis but remains elevated compared with general population.

Eosinophilic Fasciitis: A Rare Immune-Related Adverse Effect of Immune Checkpoint Inhibitor Therapy

By

Susan Moench, PhD, PA-C

Diagnosis and management of EF in the setting of cancer immunotherapy requires close collaboration between patient’s oncologist, dermatologist, and rheumatologist.

Antibiotic Prophylaxis Reduced Febrile Episodes, Death in Newly Diagnosed Myeloma in TEAMM Trial

By

Megan Garlapow, PhD

The TEAMM trial sought to assess time to first febrile episode or death from all causes in patients with newly diagnosed myeloma who received antibiotic prophylaxis vs those who did not.